Drug Type Small molecule drug |
Synonyms TGR-326, TGRX 326, TGRX326 |
Target |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | Phase 3 | CN | Shenzhen TargetRx, Inc.Startup | 06 Dec 2023 |
Non-Small Cell Lung Cancer | Phase 1 | - | Shenzhen TargetRx, Inc.Startup | 15 Jun 2024 |
NCT05441956 (ASCO2023) Manual | Phase 1 | ALK positive Non-Small Cell Lung Cancer ALK Positive | 185 | cdnujtlzdi(jfdsdkmqlt) = axhkcgnzjz uiedzhngnv (ncjhkkfhjh ) View more | Positive | 31 May 2023 | |
(Prior 1 ALK TKI) | cdnujtlzdi(jfdsdkmqlt) = zuazntxami uiedzhngnv (ncjhkkfhjh ) View more |